

1 **CRISPR-mediated detection of *Pneumocystis* transcripts in bronchoalveolar, oropharyngeal, and serum**
2 **specimens for *Pneumocystis* pneumonia diagnosis**

3

4 Brady M. Youngquist^{1*}, Ayanda Trevor Mnguni^{2, 3*}, Dora Pungan^{4*}, Rachel PJ Lai⁵, Guixiang Dai⁴, Chun Fai Ng⁶,
5 Amy Samson⁷, Yasmean Abdelgalil¹, Christopher J. Lyon¹, Bo Ning¹, Shahid Husain⁶, Sean Wasserman⁸, Jay
6 K. Kolls^{4**} and Tony Y. Hu^{1**}

7

8 **Author Affiliations:**

- 9 1. Center for Cellular and Molecular Diagnostics, Department of Biochemistry and Molecular Biology,
10 School of Medicine, Tulane University, New Orleans, LA, USA
- 11 2. Centre for Infectious Diseases Research in Africa, University of Cape Town, South Africa, Africa
12 Mycology Unit, University of Cape Town, South Africa, Department of Internal Medicine, University of
13 Cape Town, South Africa
- 14 3. Department of Internal Medicine, University of Stellenbosch, South Africa
- 15 4. Center for Translational Research in Infection and Inflammation, School of Medicine, Tulane University,
16 New Orleans, LA, USA
- 17 5. Department of Infectious Disease, Imperial College London, London, UK
- 18 6. Multi-Organ Transplant Program, Division of Infectious Diseases, Department of Medicine, University
19 Health Network/ University of Toronto, Toronto, ON M5G 2N2, Canada
- 20 7. Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa
- 21 8. St. George's University, London, UK

22 *These authors contributed equally to this work.

23 ****Corresponding authors:** Jay K. Kolls (jkolls1@tulane.edu, 5049880455, 333 S Liberty St, JBJ Rm 375, New
24 Orleans, LA 70112) or Tony Hu (tonyhu@tulane.edu, 5046058004, 333 S Liberty St, JBJ Rm 474, New Orleans,
25 LA 70112).

26 **Conflict of interest statement:** The authors have declared that no conflict of interest exists.

Abstract

Background. *Pneumocystis jirovecii* pneumonia (PCP) is a leading cause of fungal pneumonia, but its diagnosis primarily relies on invasive bronchoalveolar lavage (BAL) specimens that are difficult to obtain. Oropharyngeal swabs and serum could improve the PCP diagnostic workflow, and we hypothesized that CRISPR could enhance assay sensitivity to allow robust *P. jirovecii* diagnosis using swabs and serum. Herein we describe the development of an ultrasensitive RT-PCR-coupled CRISPR assay with high active-infection specificity in infant swabs and adult BAL and serum.

Methods. Mouse analyses employed an RT-PCR CRISPR assay to analyze *P. murina* transcripts in wild-type and *Rag2*^{-/-} mouse lung RNA, BAL, and serum at 2-, 4-, and 6-weeks post-infection. Human studies used an optimized RT-PCR CRISPR assay to detect *P. jirovecii* transcripts in infant oropharyngeal swab samples, adult serum, and adult BAL specimens from *P. jirovecii*-infected and *P. jirovecii*-non-infected patients.

Results. The *P. murina* assays sensitively detected *Pneumocystis* RNA in the serum of infected mice throughout infection. Oropharyngeal swab CRISPR assay results identified infants infected with *P. jirovecii* with greater sensitivity (96.3% vs. 66.7%) and specificity (100% vs. 90.6%) than RT-qPCR compared to *mtLSU* standard marker, and CRISPR results achieved higher sensitivity than RT-qPCR results (93.3% vs. 26.7%) in adult serum specimens.

Conclusion. Since swabs are routinely collected in pediatric pneumonia patients and serum is easier to obtain than BAL, this assay approach could improve the accuracy and timing of pediatric and adult *Pneumocystis* diagnosis by achieving specificity for active infection and potentially avoiding the requirement for BAL specimens.

Funding. NIH; NHLBI; NIAID; NIHR

INTRODUCTION

Molecular epidemiology evidence indicates that *Pneumocystis jirovecii* pneumonia (PCP) is the leading cause of fungal pneumonia in HIV-negative infants under 2 years old (1, 2), but PCP is also clinically relevant in adults and children with immunodeficiencies or who are receiving immunosuppressive regimens (2). *P. jirovecii* infections that cause severe disease and require mechanical ventilation can have mortality rates of 20-25% (3). Rapid PCP diagnosis is required for effective therapeutic intervention, but current diagnostic tests require an invasive bronchoalveolar lavage (BAL) procedure to obtain diagnostic specimens, which can delay diagnosis (4, 5), and use Grocott methenamine silver (GMS) or immunofluorescent staining methods or PCR of *P. jirovecii*-specific genomic DNA to detect *P. jirovecii* infection (6). However, there is evidence that an organism-specific diagnostic that uses minimally- or noninvasive-samples is needed to improve diagnosis (7-9). Direct fluorescent antibody staining of induced and expectorated sputum has variable sensitivity for *P. jirovecii* and is primarily useful in HIV-positive patients, who have higher *P. jirovecii* burdens than other PCP patients (10), while a blood-based 1,3 beta-D-glucan test used to diagnose PCP lacks specificity for *P. jirovecii* (11, 12). PCR-based assays for PCP can be more rapid, sensitive, and specific than staining procedures, but also primarily rely on BAL specimens and can detect *P. jirovecii* colonization events (*P. jirovecii* detected without pneumonia or with pneumonia caused by another pathogen). This can reduce their diagnostic value (13) since PCR values can vary widely in infected individuals, preventing the use of a universal threshold for PCP diagnosis (1, 14, 15). PCR tests have also been used to detect *P. jirovecii* DNA in oral wash, induced sputum, and serum specimens, but these tests have variable sensitivity and may also detect colonization events (7, 16-19). There is therefore still an urgent need for PCP diagnostics that use less invasive specimen types to provide rapid and accurate results that can guide treatment decisions.

Current PCR tests that target *P. jirovecii* genomic DNA can also detect *P. jirovecii* colonization events, however, there is no accepted threshold to distinguish colonization from active infection (1, 14, 20). We hypothesized that assays that detect and quantify mRNA transcripts that distinguish the troph and ascus life stages of *P. jirovecii*, rather than overall pathogen abundance, could improve specific detection of active infection, since each stage

exhibits distinct metabolic activity and behavior during colonization and active infection (21, 22). More sensitive assays may be required to detect such transcripts, however, particularly in less invasive samples where *Pneumocystis* mRNA may be less abundant or rapidly degraded by environmental hydrolases.

CRISPR (clustered regularly interspaced short palindromic repeats) reactions employed to enhance the sensitivity and specificity of nucleic acid amplification assays (23-25) have been applied to diagnose viral, bacterial, and fungal infections in minimally invasive sample types including blood, saliva, nasal swabs, and urine (25). Such approaches can substantially improve both assay specificity and sensitivity, since target amplification and detection relies on specific binding of a reverse transcription (RT) primer (for an RNA target), PCR amplification primers, and a guide RNA sequence that mediates the binding and trans-cleavage activity of a target-specific CRISPR Cas complex that can be employed to cleave a quenched reporter nucleotide and amplify the assay readout signal (23, 26). We therefore developed RT-PCR CRISPR Cas12a assays to sensitively and specifically detect *Pneumocystis* mRNAs that differentially overexpressed in the troph and ascus stages of *P. jirovecii* and *P. murina*, a closely related species that causes fungal pneumonia in mice (21).

Here, we describe the development and characterization of these assays and their performance to detect these stage-selective mRNA targets in serum and BAL samples of *P. murina*-infected mice and oropharyngeal swab in *P. jirovecii*-infected infants, and serum and BAL specimens of adult PCP patient cohorts. Our results detected differential increased expression of the troph vs. ascus marker in immunocompromised *Rag2^{-/-}* mice at increased risk for active infection vs. wild-type mice. Similarly, we observed that the *P. jirovecii* troph marker exhibited greater specificity for adults and infants diagnosed with PCP, although both markers were overexpressed in these cases, and that there was clear signal separation in individuals diagnosed with and without PCP. These results suggest that similar assays could be employed with oropharyngeal swabs and serum to improve the diagnosis and monitoring of PCP cases required to improve patient outcomes.

RESULTS

Study Design for RT-PCR CRISPR clinical validation

RT-PCR CRISPR assays were developed and used to blindly analyze 107 retrospectively collected oropharyngeal swab samples obtained from the PERCH cohort (1), an international case-control study designed to analyze the incidence of pathogens that cause pneumonia in infants (Supplemental Table 1). This study examined samples collected from children aged 1-59 months who were admitted to the hospital with severe pneumonia and age-matched healthy controls from the same general communities, and used quantitative PCR to detect *P. jirovecii* gene *mtLSU* in extracted nucleic acid samples and a threshold of $>10^4$ copies/mL as a classifier for active disease. CRISPR and RT-qPCR assay sensitivity and specificity results were calculated against the corresponding PERCH study *mtLSU* qPCR swab results. RT-PCR CRISPR assays were also employed to blindly evaluate 32 BAL samples from 12 PCP and 20 *P. jirovecii* non-infected patients, using residual BAL specimens from PCP-positive pneumonia patients (qPCR-positive for *P. jirovecii mtLSU* DNA) or from PCP-negative patients undergoing clinical surveillance after lung transplant or for other conditions (Supplemental Table 2).

To assess the potential for blood-based PCP diagnosis, CRISPR and RT-qPCR assays were used to blindly analyze matched BAL and serum samples from a prospective cohort of 27 adult HIV-positive patients with suspected PCP who were enrolled in an observational cohort study at Khayelitsha District Hospital in Cape Town, South Africa (Figure 1). Study participants, who had dyspnea and hypoxemia ($sO_2 \leq 94\%$ or $PaO_2 \leq 10kPa$) with an abnormal chest X-ray, were provided with PCP treatment and underwent BAL collection to confirm PCP using a *P. jirovecii* immunofluorescence assay (IFA) and had serum collected at the same time.

Development and optimization of CRISPR-enhanced RT-PCR assays for two *P. murina* mRNA targets

Pneumocystis-derived biomarkers that distinguish replicating troph and non-replicating ascus spores could permit development of assays that distinguish *Pneumocystis* infection from colonization to guide treatment decisions (Figure 2). Since we previously reported *P. murina* serine protease (*Sp*) and 1,3-beta glucan synthase subunit (*Gsc1*) mRNA transcripts are differentially upregulated in its troph and ascus stages, we hypothesized

that RT-PCR CRISPR-Cas12a assays might have the sensitivity necessary to detect them in serum to permit minimally invasive infection diagnosis, and used an in silico approach to identify primer pairs and gRNAs to amplify and detect target sequences within these mRNAs (Supplemental Table 3).

RT-PCR conditions for these mRNA targets were optimized by analyzing the CRISPR signal produced when their amplicons were generated over a range of annealing temperatures with cDNA generated from lung tissue homogenates of *P. murina*-infected mice, as previously described (21). CRISPR signal-to-noise ratios defined by the signal generated with and without input template (Supplemental Figure 1, A and B) identified optimum annealing temperatures for *Sp* and *Gsc1* amplification (57.5°C and 59.9°C) that were used in all further analyses. Subsequent analyses identified the determined reporter concentration (667 pM) that produced the highest signal-to-noise ratio for the least amount of input probe (Supplemental Figure 1, C and D), and the Cas12a/gRNA concentration (67 pM) that yielded optimum signal kinetics for the amount of input Cas12a and gRNA (Supplemental Figure 1, E and F). No substantial signal increases were observed in the absence of input template, consistent with minimal reporter degradation.

Linearity and limit of detection (LoD) values for these optimized *Sp* and *Gsc1* RT-PCR CRISPR assays were then determined using serial dilutions of synthetic *Sp* or *Gsc1* DNA fragments spiked into healthy serum (10^6 to 10^{-1} copies/ μ L) (Supplemental Figure 2, A and B). These *Sp* and *Gsc1* assays detected positive signals in serum concentration standards spiked with 0.3 and 1 copies/ μ L, respectively, and had strong linear correlations with the spiked-in target amount (R^2 values of 0.990 and 0.983) from their LoDs to the highest analyzed target concentration (10^4 copies/ μ L) (Supplemental Figure 2, C and D). *Sp* and *Gsc1* assay signal also demonstrated strong species-specificity since positive signal was not detected when these assays were used to analyze genomic RNA or DNA of an array of common viral and microbial respiratory pathogens, including the related human pathogen *P. jirovecii* (Supplemental Figure 2, E and F).

***Sp* and *Gsc1* detection in BAL and serum of *P. murina*-infected wildtype and *Rag2*^{-/-} mice**

Sp and *Gsc1* RT-PCR CRISPR assay were then used to analyze lung tissue, BAL, and serum specimens collected from C57BL6/J wildtype (WT) and immunocompromised (*Rag2*^{-/-}) mice sacrificed two-, four-, and six-weeks after inoculation with *P. murina* (Figure 3A), as this model reflects critical aspects of human disease (27, 28). Lung tissue *Sp* mRNA expression was higher in *Rag2*^{-/-} versus WT mice, and *Gsc1* mRNA expression was

higher in the lungs of WT versus *Rag2*^{-/-} mice (Figure 3, B and C). Lung tissue *Sp* and *Gsc1* signal did not vary over time in *Rag2*^{-/-} mice, but both significantly decreased at six weeks post-inoculation in the WT mice, potentially indicating infection clearance. *Sp* and *Gsc1* signal was less reliably detected in the BAL and serum samples of these mice (Figure 3, D-G), particularly the WT mice. *Sp* and *Gsc1* signal was consistently detected in *Rag2*^{-/-} mouse BAL and serum specimens at four weeks post-inoculation, but signal for both targets was more variable in the matching WT mouse samples, and in samples collected at two weeks post-inoculation in both groups. *Sp* and *Gsc1* signals tended to be greater in *Rag2*^{-/-} mouse BAL versus serum specimens, and *Sp* signal tended to be consistently greater than *Gsc1* signal throughout infection, consistent with a reduced ability of the *Rag2*^{-/-} mice to suppress their *P. murina* infections as neither difference was detected in the WT mouse samples. *Sp*-positive *Rag2*^{-/-} mouse BAL and serum samples also tended to be *Gsc1*-positive by week two post-inoculation, with double positive results detected in all *Rag2*^{-/-} mouse BAL and serum samples by week four post-inoculation. By contrast, BAL and serum samples of the WT mice tended to be *Sp*-negative and *Gsc1*-negative at week two post-inoculation, sporadically positive for both markers at week four post-inoculation, and mostly negative for both markers at week six post-inoculation consistent with greater containment of their *P. murina* infections.

Development and optimization of CRISPR-enhanced RT-PCR assays for *P. jirovecii* RNA targets

We next translated this approach to detect troph and ascus targets of *P. jirovecii*, as this human pathogen is closely related to *P. murina*. However, while a *P. jirovecii*-specific *Gsc1* primer and gRNA set produced strong signal, those generated for the *Sp* homolog of *P. jirovecii* did not produce detectable signal (data not shown), likely due to low confidence in *P. jirovecii* *Sp* sequence data or polymorphisms. We therefore instead identified *P. jirovecii* RNAs that were differentially expressed and abundant detected in a RNAseq dataset of BAL specimens from two immunocompromised patients diagnosed with *P. jirovecii* infections (29). Similar to previous work indicating that mitochondrial transcripts are enriched in troph-derived *P. murina* RNA, *P. jirovecii* mitochondrial RNAs were the most abundant differentially enriched transcripts detected in these samples (Figure 4, A and B), consistent with a previous study indicating that the trophic form of *P. jirovecii* plays a dominant role in pulmonary infections and that troph-derived *P. murina* RNA is enriched for mitochondrial RNA transcripts (21). NADH-ubiquinone oxidoreductase chain 4 (*Nad4*) was selected for further analysis since primers to this RNA

amplified a region containing a candidate gRNA sequence with a conserved protospacer adjacent motif (PAM) site required for efficient Cas12a target recognition and cleavage activity. These primers and gRNA sequences were designed to avoid known *Nad4* SNPs that might affect their binding and detection and lack substantial homology with corresponding *Nad4* sequences of other *Pneumocystis* species.

CRISPR signal-to-noise ratio analyses determined that annealing temperature (59.9°C) and reporter probe and Cas12a/gRNA complex concentration (67 pM and 67pM) conditions for optimal *P. jirovecii* *Nad4* and *Gsc1* RT-PCR Cas12a reactions were similar to those identified for the *P. murina* assays (Supplemental Figure 3). The *P. jirovecii* *Nad4* and *Gsc1* assays had LoD values (0.1 and 1 copies/μL) (Figure 4, C and D) that closely matched those of the corresponding *P. murina* assays, while the LoD value of the equivalent *Nad4* RT-PCR assay was 100× greater than the *Nad4* RT-PCR CRISPR assay (10 copies/μL) (Figure 4E). These RT-PCR CRISPR assays and RT-qPCR revealed strong linear correlations between signal and spiked-in target (R^2 values of 0.936, 0.927, 0.99) from their individual LoDs to the highest analyzed target concentration (10^4 copies/μL) (Figure 4, F-H). Finally, both RT-PCR CRISPR assays demonstrated strong species-specificity since strong positive signal was detected in the *P. jirovecii* positive control sample, while negative control samples containing corresponding DNA regions from other respiratory pathogens, including *P. murina*, did not produce signal greater than that detected in the non-template control sample (Figure 4, I and J).

***P. jirovecii* *Nad4* and *Gsc1* assay performance with patient BAL and oropharyngeal swab specimens**

For oropharyngeal swab analysis, tested samples were primarily from infants <12 months of age (2 children were >12 months of age). *Nad4* and *Gsc1* signal thresholds distinguished infants with and without *P. jirovecii* infections with 96.3% and 72.2% sensitivity and 100% specificity (Figure 5, A and B, Supplementary Figure 4A, and Table 1), while the *Nad4* RT-qPCR threshold for positive signal had 66.7% diagnostic sensitivity and 90.6% specificity. Similarly, an analysis of adult BAL specimens (12 PCP and 20 non-PCP cases, including one HIV-positive PCP patient), detected PCP cases with 91.7% and 83.3% clinical sensitivity and 100.0% specificity (Figure 5C, Supplementary Figure 4B, and Table 2), while *Nad4* RT-qPCR results had 66.7% diagnostic sensitivity and 94.7% specificity. CRISPR *Nad4* and *Gsc1* assay results had better overall classification performance than RT-qPCR *Nad4* assay results to distinguish cases and controls in infant swab and adult BAL sample cohorts when these results were evaluated in receiver operating characteristic curve analyses (Supplementary Figure 5).

***P. jirovecii* Nad4 and Gsc1 assay performance with matched patient BAL and serum specimens**

CRISPR *Nad4* signal in BAL specimens from South Africa distinguished PCP-positive and PCP-negative patients with 100% sensitivity and 91.7% specificity, exceeding CRISPR *Gsc1* (73.3% sensitivity / 75.0% specificity) and RT-qPCR *Nad4* (60.0% sensitivity / 83.3% sensitivity) diagnostic performance (Figure 5D, Table 3, Supplementary Figure 6A). CRISPR *Nad4* and *Gsc1* results for serum identified PCP-positive patients with 93.3% and 60.0% sensitivity, respectively, and 91.7% specificity, which also exceeded the performance (26.7% sensitivity / 91.7% specificity) of the matching RT-qPCR *Nad4* results (Figure 5E, Table 4, Supplementary 6B). *Nad4* levels detected in these samples demonstrated higher mean fluorescent intensity in BAL versus serum specimens (Figure 5, F and G). CRISPR *Nad4* assay results from adult BAL and serum samples also had better performance to distinguish adult PCP and non-PCP cases than matching *Gsc1* assay results when both were evaluated by receiver operating curve analysis (Supplementary Figure 7).

DISCUSSION

New PCP diagnostic tests that employ minimally or non-invasive specimens and distinguish infection from colonization are needed to improve PCP diagnosis, since collecting diagnostic BAL specimens can delay diagnosis and rapid and sensitive PCR-based assays for *P. jirovecii* genomic DNA lack accepted thresholds to distinguish colonization and infection. Herein we describe the development of an ultrasensitive RT-PCR CRISPR assay to detect mRNA targets enriched in the replicating *Pneumocystis* trophic stage associated with active infection and the non-replicating ascus stage, and the performance of these assays to detect *Pneumocystis* infections in a mouse model of *P. murina* pneumonia and in adult and infant cohorts of *P. jirovecii* infection using BAL specimens or less invasive samples, including serum and oropharyngeal swabs. CRISPR-mediated signal enhancement was necessary to achieve robust diagnostic sensitivity as it markedly increased the performance of RT-qPCR for *Nad4* mRNA when applied to analyze infant oropharyngeal swab (96.3% versus 66.7%), adult serum (93.3% vs. 26.7%) samples, adult BAL specimens obtained from North American (91.7% versus 66.7%) and South African patient cohorts (100% vs. 60.0%).

We have previously used similar CRISPR-Cas12a assay approaches to diagnose respiratory infections caused by other pathogens, including SARS-CoV-2 and *Mycobacterium tuberculosis*, using minimally- or non-invasive sample types such as blood and saliva (30-32), while another group has used CRISPR to diagnose PCP (33). This group used a CRISPR Cas13-based assay approach to detect a *P. jirovecii* mitochondrial large subunit ribosomal RNA target in RNA extracts of patient BAL specimens after transcription-mediated amplification. Notably, this approach differs from ours in at least one key aspect since its target was selected for its abundance, repetitive sequence, and frequent citation, not for its ability to distinguish the replicative troph and non-replicative ascus stages of *P. jirovecii* or colonization from infection. This Cas13 assay yielded higher limit of detection (2 versus 0.1 copies/ μ L) and lower sensitivity estimates (78.9% vs. 91.7% and 100%) with BAL specimens than our Cas12a assay, but achieved similar diagnostic specificity (97.7% vs. 100% and 91.7%). No alternate samples were analyzed in this Cas13-based study, however, preventing further comparisons.

Infant swab samples analyzed in this study were obtained from the case-control PERCH study, which used a quantitative multiplex polymerase chain reaction assay to examine causes of severe pneumonia in children aged 1-59 months who were hospitalized with severe pneumonia and age-matched healthy controls from the same general population (1). The PERCH study analyzed oropharyngeal swab and induced sputum specimens from these infants and observed high agreement (94.6%) between results of these specimens (34), supporting the potential utility of swab results for the diagnosis of *P. jirovecii*-infections in this cohort. However, induced sputum results for individual patients were not available for use as the reference standard in our analysis.

The PERCH study detected *P. jirovecii* DNA in oropharyngeal samples collected from cases and controls at similar frequency, likely due to high rates of pulmonary colonization in the healthy control group. Other studies have established thresholds for PCP diagnosis to address this problem, but these values vary among studies and there is no standard threshold to distinguish infection from colonization (14, 15, 35, 36). One study has reported that PCR analysis of a single versus multicopy gene can improve specificity for infection versus colonization events, although this may also reduce assay sensitivity (37). Our results indicate that CRISPR-mediated *Nad4* RNA detection could address this issue since *Nad4* signal was not detected above background in specimens of most individuals not diagnosed with PCP, but had high diagnostic sensitivity (91.7%-100%) for *P. jirovecii*-infected infants and PCP adult cases. We were not able to directly compare the results from BAL and oropharyngeal swabs in this study since both sample types were not available from the infant or adult cohorts.

We detected elevated levels of the troph marker *Sp* in serum and BAL samples of *Rag2*^{-/-} vs. wildtype mice inoculated with *P. murina*, consistent with prior reports that *Rag2*^{-/-} mice have higher troph life form burden during active *P. murina* infection (21). Future mouse model experiments should investigate changes in the relative abundance of *P. murina* troph and ascus stages during active infection initiation, colonization, and reactivation, and potentially animal-to-animal versus environmental transmission, and other important questions. For example, specific depletion of asci by treating *P. murina*-infected mice with echinocandins could validate the troph-specific expression of *Sp* (and the *P. murina Nad4* homolog) (21, 38). Serum could be a less invasive option than BAL for PCP diagnosis, although it is easier to obtain oropharyngeal swabs from infants than serum. Other studies have analyzed *P. jirovecii* cell-free DNA using PCR in human serum samples with variable

sensitivity (50-100%) likely due to dilute concentration of cell-free DNA targets, and one of these studies had a substantial drop in specificity when testing serum from healthy blood donors (100%) and HIV-patients (71%) possibly due to colonization detection (9, 16, 39). We observe a slight decrease in sensitivity when testing serum versus BAL (93.3% vs. 100.0%), although specificity did not differ for these sample types (91.7%). Notably, the single false-positive sample detected had positive CRISPR *Nad4* results for their matching BAL and serum specimens. However, additional information was not available to evaluate whether this patient was a missed PCP-positive case, had *P. jirovecii* colonization, or was accurately assessed as a true negative.

Pneumocystis cell-free RNA was less frequently detected in serum versus BAL or lung tissue specimens of the *P. murina*-infected mice, but signal for the troph-enriched *Sp* target was consistently lower than *Gsc1* signal in all specimen types of the WT versus *Rag2*^{-/-} mice, consistent with reduced ability of the *Rag2*^{-/-} mice to suppress their *P. murina* infections. *Nad4* was selected as a *P. jirovecii* troph marker since its elevated expression is consistent with increased metabolic activity of replicating *P. jirovecii* trophs, and it revealed greater diagnostic sensitivity for *P. jirovecii* infection than the ascus marker *Gsc1* when both were analyzed in oropharyngeal swab (96.3% versus 72.2%), BAL (91.7% and 100% versus 83.3% and 73.3%), or serum (93.3% versus 60.0%) specimens. However, the diagnostic performance of *Gsc1* suggests that sensitive detection of any *P. jirovecii* RNA target may enable PCP diagnosis given that rapid RNA degradation expected in diagnostic specimens might limit detection of low burden colonization events.

CRISPR *Nad4* assay results demonstrated high specificity for *P. jirovecii* infections in this study, suggesting that studies designed to detect *P. jirovecii*-specific RNA or DNA targets in minimally or non-invasive diagnostic specimens from large, well-characterized cohorts could be used to evaluate transmission among close contacts, the incidence of PCP and *P. jirovecii* colonization, and its environmental prevalence (40, 41). Further studies could also clarify the clinical impact of *P. jirovecii* colonization, which has been linked to COPD severity and is frequently detected during autopsy (42, 43), particularly since the incidence of *Pneumocystis* colonization differs for the general population (~25%), healthcare workers (>50%), and HIV-positive individuals (~69%) (40, 44). Although *P. jirovecii* is an obligate pathogen and humans are likely the only reservoir as *P. jirovecii* cannot infect mice, rats, and nonhuman primates (45-48), *P. jirovecii* DNA has been detected in pond water and air samples,

and the prevalence of *P. jirovecii* infection is higher in areas with more green space (49), suggesting *P. jirovecii* may survive briefly in an environmental reservoir.

Rapid detection of *P. jirovecii*-infected infants using oropharyngeal swab specimens may have substantial clinical relevance since *P. jirovecii* is likely underdiagnosed in the months following birth and has the potential to produce fatal outcomes (50, 51). We propose that a CRISPR-based approach similar to the one described here could be used to analyze the impact of *P. jirovecii* in infants with and without pneumonia, following validation studies, as it should permit accurate high-throughput screening of swab specimens routinely collected from infants (52). CRISPR diagnostics are a relatively new technology, but multiple clinical trials are ongoing to diagnose respiratory infections, including pneumonia, using CRISPR-based approaches (53-55). *P. jirovecii* point-of-care methods that use PCR-based assays and noninvasive samples are cheaper than tests that employ BAL specimens (56), and assays that use other noninvasive sample types could also improve diagnostic reliability by attenuating or eliminating sample-to-sample variation and dilution errors that affect the analysis of BAL specimens (57, 58). Multiple studies have developed tests that use induced sputum, but these specimens are also subject to sample-to-sample variation, must be analyzed for sample quality when analyzing infant specimens, and cannot be feasibly collected from healthy controls for specificity tests (34, 59). New diagnostics could also be adapted to formats and workflows suitable for analysis by inexpensive point-of-care devices in resource-limited settings, as has been done for CRISPR-based assays that detect other respiratory pathogens (30, 32). Loop-mediated isothermal amplification (LAMP)-based assays that use a turbidity readout to detect *P. jirovecii* 18s rRNA gene have been reported, but these use invasive BAL specimens or highly variable induced sputum samples and target *P. jirovecii* DNA, which increases likelihood of detecting colonization (60-62).

This study has limitations that may complicate interpretation of its results. For example, *Nad4* assay sensitivity and specificity estimates could be affected by *P. jirovecii* colonization, as the presence or absence of active fungus was not confirmed in all samples. However, it is difficult to account for *P. jirovecii* colonization as there is no gold standard for colonization other than histologic analysis of stained BAL samples, which is not realistic in healthy populations. We also cannot evaluate the diagnostic performance of the *Nad4* assay with adult

326 oropharyngeal swab or infant serum specimens, as our cohort lack these samples. The sensitivity and specificity
327 calculations for the adult cohorts in this study are underpowered and subject to substantial variation in future
328 studies. Nevertheless, we believe that similar, validated CRISPR-based assay approaches could improve *P.*
329 *jirovecii* diagnosis and could be incorporated into multiplex CRISPR assays to detect an array of fungal, bacterial,
330 and viral pathogens that cause pneumonia from a single swab specimen.

METHODS

Sex as a biological variable

Patient sexes used in this study are specified in Supplementary Table 1 and 2. Sex was not considered as a biological variable.

Mice Female C57BL/6J wild-type and Rag2^{-/-}(B6(Cg)-Rag2tm1.1Cgn/J) mice aged 6- to 8-weeks were obtained from The Jackson Laboratory (Bar Harbor, ME) and housed in a pathogen-free environment at the Tulane University Department of Comparative Medicine.

Mouse *P. murina* infection procedure All mice were infected with *P. murina* by oropharyngeal administration as previously published (28, 29, 63). Mice were lightly anesthetized with 2% isoflurane delivered in a box connected to the delivery machine and then fixed vertically on a surgery board, the tongue was extended with forceps, and a 100 µL inoculum containing 2x10⁵ *P. murina* cysts was administered to the distal part of the oropharynx using a micropipette while gently closing the nose. At 2-, 4-, and 6-weeks post-inoculation, mice were euthanized by carbon dioxide inhalation to collect BAL, sera, and lung tissue specimens.

RNA isolation Mouse serum cell-free (cf) RNA was extracted using a Quick-cfDNA/cfRNA Serum & Plasma Kit (Zymo Research, R1072). RNA was extracted from all other samples analyzed using a Quick-RNA Fungal/Bacterial Miniprep Kit (Zymo Research, R2014). All RNA isolates were eluted in 50 µL of DNase/RNase-free water and stored at -80 °C until analysis. Positive control and negative control samples were derived from samples from healthy mice or individuals that were then spiked with *P. murina* or *P. jirovecii* RNA or water, respectively.

RT-PCR CRISPR analyses RT-PCR reactions were generated by adding 5 µL isolated RNA to a mixture containing 10 µL 2x Platinum SuperFi RT-PCR master Mix (Thermo Fisher, 12594025), 0.2 µL SuperScript IV RT Mix (Thermo Fisher, 12594025), 1 µL of 10 µM forward primer, 1 µL of 10 µM reverse primer, and 2.8 µL of nuclease free-water. For RT-PCR-CRISPR experiments, 5 µL isolated *P. murina* or *P. jirovecii* RNA was added as template and water was added for the no template controls. RT-PCR reaction was first incubated at 25 °C for 2 minutes and 55 °C for 10 minutes to permit cDNA synthesis, and then denatured at 95°C for 5 minutes, subjected to 38 cycles of PCR amplification [95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 15

seconds], and then incubated at 72°C for 5 minutes to permit complete extension of all amplicons. CRISPR reaction mixtures containing: 25.48 µL nuclease-free water, 0.01 µL 66.7 µM IDT Lb Cas12a (Integrated DNA Technologies, 10007922) , 0.01 µL 100 µM gRNA, 1.5 µL of the 10 µM fluorescent reporter, and 3 µL NEBuffer 2.1 (New England Biolabs, B7202) were supplemented with a 2 µL aliquot the final RT-PCR reaction sample and incubated at 37 °C for 15 minutes in the dark in a 96 well corning half area opaque plate. CRISPR reactions analyzing *P. murina* and *P. jirovecii* RT-PCR reaction samples were respectively analyzed using a SpectraMax i3x Multi-Mode Microplate Reader (Molecular Devices) and an Infinite M Plex (Tecan) plate reader, using 485 nM excitation and 525 nM emission settings. Thresholds for positive CRISPR signal in spiked samples and clinical samples were defined as the mean plus three times the SD of the signal detected in triplicate no-template control samples.

Standard curve and limit of detection (LoD) analyses Serum samples used to generate the standard curves for the *P. murina* and *P. jirovecii* RT-PCR CRISPR assays were generated by spiking known concentrations of the appropriate *P. murina* or *P. jirovecii* synthetic gBlock target DNA sequence (*Sp* or *Gsc1* and *Nad4* or *Gsc1*) into healthy mouse serum or swab RNA isolation solution, respectively. These concentration standards were then subjected to 10-fold serial dilutions in serum or swab diluent to generate concentration standards that contained from 10⁻¹ to 10⁶ copies/µL of these target sequences. These concentration standards were then processed to isolate DNA that was analyzed in RT-PCR CRISPR assays for the appropriate target sequence.

RT-qPCR RT-PCR reactions were performed with SuperScript IV First-Strand Synthesis System kits and random hexamers (Thermo Scientific) and the resulting cDNA was isolated using AMPure XP Beads (Beckman Coulter, A63880) and 80% ethanol before use in qPCR reactions employing 10 µL SsoAdvanced Universal Probes Supermix (2x) (Bio-Rad, 172-5280), 0.9 µL forward primer (20 µM), 0.9 µL reverse primer (20 µM), 0.45 µL probe (20 µM), 5.75 µL nuclease-free water, and 2 µL cDNA template. Reactions were performed by incubating the reactions at 50°C for 2 minutes and 95°C for 10 minutes, and then using 50 cycles of 95°C for 15 seconds and 60 °C for 30 seconds for target amplification. Melt curve were performed from 55 to 95°C with 0.5 °C increments after reaction completion to confirm that the reaction amplified a single product with the expected melting

temperature profile. Thresholds for positive RT-qPCR signal in spiked samples were defined as the mean plus three times the SD of the signal detected in triplicate no-template control samples. Thresholds for positive RT-qPCR signal in clinical samples were determined by receiver operating characteristic curve analyses.

Clinical sample collection procedures Oropharyngeal swabs analyzed in this study were obtained from children between 1-59 months Table S2; 54 *P. jirovecii*-infected and 53 *P. jirovecii*-non-infected). *P. jirovecii*-infected cases enrolled in the PERCH cohort study were judged to be infected with *P. jirovecii* if their analyzed swab samples yielded greater than 10^4 copies/mL of *mtLSU* DNA when analyzed using a quantitative multiplex polymerase chain reaction assay (FTD Resp-33 kit; Fast-track Diagnostics, Sliema, Malta). *P. jirovecii*-non-infected controls were age-matched with cases and selected from communities near the study sites. Children were deemed HIV-positive if HIV virus was detected in their serum samples or if the child was seropositive for HIV at greater than 12 months of age. Swabs were collected in viral transport medium (universal transport medium [UTM], Copan Diagnostics, Brescia, Italy) and processed to extract nucleic using the NucliSENS easyMAG platform (bioMerieux, Marcy l'Etoile, France) (64). Adult BAL samples collected in Toronto and New Orleans represented residual clinical pathology laboratory samples and were sampled according to clinical guidelines (65). *P. jirovecii*-positive and *P. jirovecii*-negative BAL specimens were obtained from adult patients with pneumonia or who underwent clinical surveillance following lung transplant or in response to other conditions and whose BAL samples respectively tested positive and negative when analyzed by RealStar *Pneumocystis jirovecii* PCR kit 1.0 (Altona Diagnostics). Adult serum and BAL specimens obtained from South Africa were collected as part of an NIHR funded prospective observational study aimed at describing outcomes and evaluation of non-invasive diagnostic tests for HIV-associated PCP. Consecutive adults with probable (clinical case definition) or definite (immunofluorescent staining on a respiratory sample) HIV-associated PCP were enrolled from a District Hospital in the township of Khayelitsha, Cape Town. Eligible participants underwent bronchoscopy and evaluation for co-infections. Bronchoscopies and BAL sample collections were performed by a respiratory physician using a flexible fiber-optic bronchoscope. Procedures were performed through the oral cavity following local anesthesia (lidocaine 2%) and were supported by cardiopulmonary monitoring (continuous assessment of pulse rate, blood pressure, and oxygen saturation). All BAL samples are obtained from areas of lung infiltration, and if multiple areas were observed the samples were obtained from the area where the infiltration was most severe.

RNA sequencing RNA was extracted with the Trizol method from the BAL cells pellets of two patients with Bare Lymphocyte Syndrome who had clinical PCP. Prior to construction of an Illumina total RNA library, DNase treated RNA was quantitated using a Qubit RNA BR assay kit (Thermo Fisher Scientific: Guide MAN0001987 MP10210, Kit #Q10210). Cytoplasmic, mitochondrial, and bacterial rRNA was removed from 2.5 ug of each sample as indicated by the Illumina RiboZero RNA Removal Kit Reference Guide [(Document # 15066012 v02, ScriptSeq Complete Gold (Epidemiology) Kit #BEP1206 (now obsolete)]. Illumina-compatible cDNA libraries were generated according to the instructions of the TruSeq Stranded Total RNA Sample Preparation Guide (Illumina Document #1000000040499v00, Kit #20020596). All libraries were pooled and denatured following the standard normalization method described by the Illumina Denature and Dilute Libraries Guide for the NextSeq System (Illumina Part #15048776), after which denatured libraries were loaded onto an Illumina NextSeq 550. To determine transcript abundance, FASTQ outputs were aligned to the *Pneumocystis jirovecii* RU7 genome using EdgeR normalization (66).

Statistics Statistical analyses were performed using GraphPad Prism 10 software, where p-values of less than 0.05 were used to determine statistically significant differences between groups when analyzed by parametric or non-parametric T-tests according to their data characteristics.

Study approval Adult BAL samples analyzed in this study were obtained from residual de-identified clinical diagnostic specimens using an institutional review board (IRB)-approved informed consent process at Ochsner Medical Center – New Orleans (Pro00015109) and University Health Network Toronto (13-7093). Adult BAL and serum specimens from the South African cohort were collected as part of a prospective observational cohort study performed in compliance with a protocol approved by the University of Cape Town Human Research Ethics Committee (HREC 543/2022). The Tulane University IRB reviewed the analysis protocol for the de-identified PERCH oropharyngeal swab samples (protocol 2021-1332) and determined it to be non-human-subject research. Mouse model studies were performed in compliance with a protocol approved by the Tulane Institutional Animal Care and Use Committee (protocol 1821). All study participants or parents or guardians of study participants gave written informed consent.

Data availability No original code was generated for this study and all reported data is available from the lead author upon request. Sequencing data for this study is available at GEO accession number GSE289324. Values for all data points in the graphs are reported in the Supporting Data Values file.

460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481

Author Contributions

Designing research studies, BMY, SH, ATM, RPL, SW, BN, JKK, TYH; conducting experiments, BMY, DP, GD, CN, YA; acquiring data, BMY, DP, AS, CFN; analyzing data, BMY, BN, CJL, JKK, TYH; providing reagents, JKK, TYH; writing the manuscript, BMY, CJL, JKK, TYH. BMY was listed first because he developed the CRISPR assay used in the paper.

Acknowledgements

The work was supported by research funding provided by NIH: R01AI120033 to JKK and BN, R35HL139930 and the and the Louisiana Board of Regents Endowed Chairs for Eminent Scholars program to JKK, and by research funding provided by National Institute of Allergy and Infectious Diseases (R01AI144168, R01AI175618, R01AI173021). This research was also funded by the NIHR (project 134342) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK government. We would like to acknowledge staff at Khayelitsha District Hospital, and at the Centre for Infectious Disease Research in Africa (CIDRI-AFRICA) including Shireen Galant, Asma Toefy, Asanda Hinxha, Rene Goliath, Meagan McMaster, Ryan Johnson, and Ashleigh Barnes. Figures 1, 2a, and 3b were created using Biorender.com.

REFERENCES

1. O'Brien KL, Baggett HC, Brooks WA, Feikin DR, Hammitt LL, Higdon MM, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. *The Lancet*. 2019;394(10200):757-79.
2. Liu Y, Su L, Jiang S-J, and Qu H. Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis. *Oncotarget*. 2017;8(35):59729-39.
3. Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng MP, McDonald EG, and Lee TC. Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis. *Open Forum Infectious Diseases*. 2020;7(5).
4. Boskovic T, Stojanovic M, Stanic J, Pena Karan S, Vujasinovic G, Dragisic D, et al. Pneumothorax after transbronchial needle biopsy. *J Thorac Dis*. 2014;6(Suppl 4):S427-34.
5. Carmona EM, and Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. *Therapeutic Advances in Respiratory Disease*. 2011;5(1):41-59.
6. Bateman M, Oladele R, and Kolls JK. Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches. *Med Mycol*. 2020;58(8):1015-28.
7. Senecal J, Smyth E, Del Corpo O, Hsu JM, Amar-Zifkin A, Bergeron A, et al. Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2022;28(1):23-30.
8. White PL, Posso RB, Gorton RL, Price JS, Wey E, and Barnes RA. An evaluation of the performance of the Dynamiker® Fungus (1-3)- β -D-Glucan Assay to assist in the diagnosis of Pneumocystis pneumonia. *Medical Mycology*. 2018;56(6):778-81.
9. Hammarström H, Grankvist A, Broman I, Kondori N, Wennerås C, Gisslen M, et al. Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and

1,3-β-D-glucan in HIV-infected patients: a retrospective case control study. *BMC Infectious Diseases*. 2019;19(1).

10. Choe PG, Kang YM, Kim G, Park WB, Park SW, Kim HB, et al. Diagnostic value of direct fluorescence antibody staining for detecting *Pneumocystis jirovecii* in expectorated sputum from patients with HIV infection. *Med Mycol*. 2014;52(3):326-30.

11. Li WJ, Guo YL, Liu TJ, Wang K, and Kong JL. Diagnosis of pneumocystis pneumonia using serum (1-3)-beta-D-Glucan: a bivariate meta-analysis and systematic review. *J Thorac Dis*. 2015;7(12):2214-25.

12. Racil Z, Kocmanova I, Lengerova M, Weinbergerova B, Buresova L, Toskova M, et al. Difficulties in using 1,3-β-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies - high frequency of false-positive results and their analysis. *Journal of Medical Microbiology*. 2010;59(9):1016-22.

13. Reid AB, Chen SC, and Worth LJ. *Pneumocystis jirovecii* pneumonia in non-HIV-infected patients: new risks and diagnostic tools. *Curr Opin Infect Dis*. 2011;24(6):534-44.

14. Mühlethaler K, Bögli-Stuber K, Wasmer S, Von Garnier C, Dumont P, Rauch A, et al. Quantitative PCR to diagnose *Pneumocystis* pneumonia in immunocompromised non-HIV patients. *European Respiratory Journal*. 2012;39(4):971-8.

15. Fauchier T, Hasseine L, Gari-Toussaint M, Casanova V, Marty PM, and Pomares C. Detection of *Pneumocystis jirovecii* by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients. *Journal of Clinical Microbiology*. 2016;54(6):1487-95.

16. Wang D, Hu Y, Li T, Rong H-M, and Tong Z-H. Diagnosis of *Pneumocystis jirovecii* pneumonia with serum cell-free DNA in non-HIV-infected immunocompromised patients. *Oncotarget*. 2017;8(42):71946-53.

17. Goterris L, Mancebo Fernández MA, Aguilar-Company J, Falcó V, Ruiz-Camps I, and Martín-Gómez MT. Molecular Diagnosis of *Pneumocystis jirovecii* Pneumonia by Use of Oral

555 Wash Samples in Immunocompromised Patients: Usefulness and Importance of the DNA
556 Target. *Journal of Clinical Microbiology*. 2019;57(12).

557 18. Desoubeaux G, Chesnay A, Mercier V, Bras-Cachinho J, Moshiri P, Eymieux S, et al.
558 Combination of β -(1, 3)-D-glucan testing in serum and qPCR in nasopharyngeal aspirate for
559 facilitated diagnosis of *Pneumocystis jirovecii* pneumonia. *Mycoses*. 2019;62(11):1015-
560 22.

561 19. Nyamande K, Lalloo UG, York D, Naidoo M, Irusen EM, and Chetty R. Low sensitivity of a
562 nested polymerase chain reaction in oropharyngeal washings for the diagnosis of
563 pneumocystis pneumonia in HIV-infected patients. *Chest*. 2005;128(1):167-71.

564 20. Yang SL, Wen YH, Wu YS, Wang MC, Chang PY, Yang S, et al. Diagnosis of *Pneumocystis*
565 pneumonia by real-time PCR in patients with various underlying diseases. *J Microbiol Immunol*
566 *Infect*. 2020;53(5):785-90.

567 21. Eddens T, Elsegeiny W, Ricks D, Goodwin M, Horne WT, Zheng M, et al. Transcriptomic and
568 Proteomic Approaches to Finding Novel Diagnostic and Immunogenic Candidates in
569 *Pneumocystis*. *mSphere*. 2019;4(5).

570 22. Skalski JH, Kottom TJ, and Limper AH. Pathobiology of *Pneumocystis* pneumonia: life cycle,
571 cell wall and cell signal transduction. *FEMS Yeast Res*. 2015;15(6).

572 23. Huang Z, Tian D, Liu Y, Lin Z, Lyon CJ, Lai W, et al. Ultra-sensitive and high-throughput
573 CRISPR-powered COVID-19 diagnosis. *Biosens Bioelectron*. 2020;164:112316.

574 24. Huang Z, Lacourse SM, Kay AW, Stern J, Escudero JN, Youngquist BM, et al. CRISPR
575 detection of circulating cell-free *Mycobacterium tuberculosis* DNA in adults and children,
576 including children with HIV: a molecular diagnostics study. *The Lancet Microbe*.
577 2022;3(7):e482-e92.

578 25. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a
579 target binding unleashes indiscriminate single-stranded DNase activity. *Science*.
580 2018;360(6387):436-9.

26. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR–Cas12-based detection of SARS-CoV-2. *Nature Biotechnology*. 2020;38(7):870-4.
27. Shellito J, Suzara VV, Blumenfeld W, Beck JM, Steger HJ, and Ermak TH. A new model of *Pneumocystis carinii* infection in mice selectively depleted of helper T lymphocytes. *Journal of Clinical Investigation*. 1990;85(5):1686-93.
28. Elsegeiny W, Zheng M, Eddens T, Gallo RL, Dai G, Trevejo-Nunez G, et al. Murine models of *Pneumocystis* infection recapitulate human primary immune disorders. *JCI Insight*. 2018;3(12).
29. Dai G, Wanek A, Eddens T, Volden P, and Kolls JK. Toward a humanized mouse model of *Pneumocystis pneumonia*. *JCI Insight*. 2021;6(2).
30. Huang Z, LaCourse SM, Kay AW, Stern J, Escudero JN, Youngquist BM, et al. CRISPR detection of circulating cell-free *Mycobacterium tuberculosis* DNA in adults and children, including children with HIV: a molecular diagnostics study. *Lancet Microbe*. 2022;3(7):e482-e92.
31. Huang Z, Ning B, Yang HS, Youngquist BM, Niu A, Lyon CJ, et al. Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection. *Journal of Clinical Investigation*. 2021;131(7).
32. Ning B, Yu T, Zhang S, Huang Z, Tian D, Lin Z, et al. A smartphone-read ultrasensitive and quantitative saliva test for COVID-19. *Science Advances*. 2021;7(2):eabe3703.
33. Zhan Y, Gao X, Li S, Si Y, Li Y, Han X, et al. Development and Evaluation of Rapid and Accurate CRISPR/Cas13-Based RNA Diagnostics for *Pneumocystis jirovecii* Pneumonia. *Frontiers in Cellular and Infection Microbiology*. 2022;12.
34. Thea DM, Seidenberg P, Park DE, Mwananyanda L, Fu W, Shi Q, et al. Limited Utility of Polymerase Chain Reaction in Induced Sputum Specimens for Determining the Causes of Childhood Pneumonia in Resource-Poor Settings: Findings From the Pneumonia Etiology Research for Child Health (PERCH) Study. *Clinical Infectious Diseases*. 2017;64(suppl_3):S289-S300.

607 35. Perret T, Kritikos A, Hauser PM, Guiver M, Coste AT, Jaton K, et al. Ability of quantitative PCR
608 to discriminate *Pneumocystis jirovecii* pneumonia from colonization. *Journal of Medical*
609 *Microbiology*. 2020;69(5):705-11.

610 36. Maillet M, Maubon D, Brion JP, François P, Molina L, Stahl JP, et al. *Pneumocystis jirovecii*
611 (Pj) quantitative PCR to differentiate Pj pneumonia from Pj colonization in
612 immunocompromised patients. *European Journal of Clinical Microbiology & Infectious*
613 *Diseases*. 2014;33(3):331-6.

614 37. Wilson JW, Limper AH, Grys TE, Karre T, Wengenack NL, and Binnicker MJ. *Pneumocystis*
615 *jirovecii* testing by real-time polymerase chain reaction and direct examination among
616 immunocompetent and immunosuppressed patient groups and correlation to disease
617 specificity. *Diagnostic Microbiology and Infectious Disease*. 2011;69(2):145-52.

618 38. Cushion MT, Ashbaugh A, Hendrix K, Linke MJ, Tisdale N, Sayson SG, et al. Gene Expression
619 of *Pneumocystis murina* after Treatment with Anidulafungin Results in Strong Signals for
620 Sexual Reproduction, Cell Wall Integrity, and Cell Cycle Arrest, Indicating a Requirement for
621 Ascus Formation for Proliferation. *Antimicrobial Agents and Chemotherapy*. 2018;62(5).

622 39. Van Halsema C, Johnson L, Baxter J, Douthwaite S, Clowes Y, Guiver M, et al. Short
623 Communication: Diagnosis of *Pneumocystis jirovecii* Pneumonia by Detection of DNA in
624 Blood and Oropharyngeal Wash, Compared with Sputum. *AIDS Research and Human*
625 *Retroviruses*. 2016;32(5):463-6.


626 40. Medrano FJ, Montes-Cano M, Conde M, De La Horra C, Respaldiza N, Gasch A, et al.
627 *Pneumocystis jirovecii* in General Population. *Emerging Infectious Diseases*.
628 2005;11(2):245-50.

629 41. Djawe K, Daly KR, Vargas SL, Santolaya ME, Ponce CA, Bustamante R, et al.
630 Seroepidemiological study of *Pneumocystis jirovecii* infection in healthy infants in Chile using
631 recombinant fragments of the *P. jirovecii* major surface glycoprotein. *International Journal of*
632 *Infectious Diseases*. 2010;14(12):e1060-e6.

42. Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, Hogg JC, et al. Association of chronic obstructive pulmonary disease severity and colonization. *Am J Resp Crit Care*. 2004;170(4):408-13.
43. Carolina, Gallo M, Bustamante R, and Sergio. *Pneumocystis* Colonization Is Highly Prevalent in the Autopsied Lungs of the General Population. *Clinical Infectious Diseases*. 2010;50(3):347-53.
44. Morris A, Wei K, Afshar K, and Huang L. Epidemiology and Clinical Significance of *Pneumocystis* Colonization. *The Journal of Infectious Diseases*. 2008;197(1):10-7.
45. Durand-Joly I, Aliouat EM, Recourt CL, Guyot K, François N, Wauquier ML, et al. *Pneumocystis carinii* f. sp. *hominis* Is Not Infectious for SCID mice. *Journal of Clinical Microbiology*. 2002;40(5):1862-5.
46. Gigliotti F, Harmsen AG, Haidaris CG, and Haidaris PJ. *Pneumocystis carinii* is not universally transmissible between mammalian species. *Infection and Immunity*. 1993;61(7):2886-90.
47. Hauser PM. Genomic Insights into the Fungal Pathogens of the Genus *Pneumocystis*: Obligate Biotrophs of Humans and Other Mammals. *PLoS Pathogens*. 2014;10(11):e1004425.
48. Demanche C, Berthelemy M, Petit T, Polack B, Wakefield AE, Dei-Cas E, et al. Phylogeny of *Pneumocystis carinii* from 18 Primate Species Confirms Host Specificity and Suggests Coevolution. *Journal of Clinical Microbiology*. 2001;39(6):2126-33.
49. Walzer PD. The Ecology of *Pneumocystis*: Perspectives, Personal Recollections, and Future Research Opportunities. *J Eukaryot Microbiol*. 2013;60(6):634-45.
50. Zakrzewska M, Roszkowska R, Zakrzewski M, and Maciorkowska E. *Pneumocystis* pneumonia: still a serious disease in children. *Dev Period Med*. 2019;23(3):159-62.
51. Rojas P, Friaza V, García E, De La Horra C, Vargas SL, Calderón EJ, et al. Early Acquisition of *Pneumocystis jirovecii* Colonization and Potential Association With Respiratory Distress Syndrome in Preterm Newborn Infants. *Clinical Infectious Diseases*. 2017;65(6):976-81.

52. Valinetz ED, and Cangelosi GA. A Look Inside: Oral Sampling for Detection of Non-oral Infectious Diseases. *Journal of Clinical Microbiology*. 2021;59(10).
53. Yu W. Species-specific Bacterial Detector for Fast Pathogen Diagnosis of Severe Pneumonia. *ClinicalTrialsgov*. 2021.
54. Yu K. Effect of PCR-CRISPR/Cas12a on the Early Anti-infective Schemes in Patients With Open Air Pneumonia. *ClinicalTrialsgov*. 2019.
55. Zhang W. Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects. *ClinicalTrialsgov*. 2019.
56. Harris JR, Marston BJ, Sangrue N, Duplessis D, and Park B. Cost-Effectiveness Analysis of Diagnostic Options for Pneumocystis Pneumonia (PCP). *PLoS ONE*. 2011;6(8):e23158.
57. Craven V, Hausdorff WP, and Everard ML. High levels of inherent variability in microbiological assessment of bronchoalveolar lavage samples from children with persistent bacterial bronchitis and healthy controls. *Pediatric Pulmonology*. 2020;55(11):3209-14.
58. Yu Y, Liu C, Zhang Z, Shen H, Li Y, Lu L, et al. Bronchoalveolar lavage fluid dilution in ICU patients: what we should know and what we should do. *Critical Care*. 2019;23(1).
59. Murdoch DR, Morpeth SC, Hammitt LL, Driscoll AJ, Watson NL, Baggett HC, et al. Microscopic Analysis and Quality Assessment of Induced Sputum From Children With Pneumonia in the PERCH Study. *Clinical Infectious Diseases*. 2017;64(suppl_3):S271-S9.
60. Uemura N, Makimura K, Onozaki M, Otsuka Y, Shibuya Y, Yazaki H, et al. Development of a loop-mediated isothermal amplification method for diagnosing Pneumocystis pneumonia. *J Med Microbiol*. 2008;57(Pt 1):50-7.
61. Singh P, Singh S, Mirdha BR, Guleria R, Agarwal SK, and Mohan A. Evaluation of Loop-Mediated Isothermal Amplification Assay for the Detection of Pneumocystis jirovecii in Immunocompromised Patients. *Molecular Biology International*. 2015;2015:1-6.

- 682 62. Kawano S, Maeda T, Suzuki T, Abe T, Mikita K, Hamakawa Y, et al. Loop-mediated isothermal
683 amplification with the Procedure for Ultra Rapid Extraction kit for the diagnosis of
684 pneumocystis pneumonia. *J Infect Chemother*. 2015;21(3):224-6.
- 685 63. Noell K, Dai G, Pungan D, Ebacher A, McCombs JE, Landry SJ, et al. Germline IgM predicts T
686 cell immunity to Pneumocystis. *JCI Insight*. 2022;7(17).
- 687 64. Driscoll AJ, Karron RA, Morpeth SC, Bhat N, Levine OS, Baggett HC, et al. Standardization of
688 Laboratory Methods for the PERCH Study. *Clin Infect Dis*. 2017;64(suppl_3):S245-S52.
- 689 65. Patel PH, Antoine MH, and Ullah S. *StatPearls*. Treasure Island (FL); 2023.
- 690 66. Robinson MD, McCarthy DJ, and Smyth GK. `edgeR`: a Bioconductor package for
691 differential expression analysis of digital gene expression data. *Bioinformatics*. 2010;26(1):139-
692 40.
- 693



695 **Figure 1 Study Participants from Cape Town, South Africa.** RT-PCR CRISPR was evaluated by blind
 696 analysis of BAL and serum from a cohort of 27 HIV-positive adults from South Africa with and without PCP
 697 confirmed by *Pneumocystis jirovecii* immunofluorescence. Study participants were enrolled with dyspnea and
 698 hypoxemia ($\text{sO}_2 \leq 94\%$ or $\text{PaO}_2 \leq 10\text{kPa}$) and an abnormal chest X-ray. BAL and serum were obtained from
 699 patients at baseline before treatment initiation, and diagnosis was achieved from collected BAL specimens using
 700 the *P. jirovecii* immunofluorescence assay.

701

702




Figure 2 Overview of the RT-PCR CRISPR assay workflow for *P. jirovecii* diagnosis. (A) RNA isolates from oropharyngeal swab or serum specimens are subjected to RT-PCR to amplify a target mRNA differentially expressed in the fungal trophic form required for active infection. These amplicons are recognized by a Cas12a/gRNA complex that cleaves and derepresses a quenched fluorescent probe in proportion to amplicon abundance. **(B)** DNA and mRNA phenotypes expected in children with *P. jirovecii* colonization and infection events and **(C)** characteristics of conventional qPCR and proposed RT-PCR CRISPR assays for *P. jirovecii* infection.




Figure 3 *Sp* and *Gsc1* assay performance in serial BAL and serum from *P. murina*-infected mice. (A) Scheme showing mouse infection and sampling time course with analysis of *P. murina* ascus- and trophic-life form transcripts *Sp* and *Gsc1*. *Sp* and *Gsc1* assay signal in mouse (**B and C**) lung RNA, (**D and E**) BAL and (**F and G**) serum at two-, four-, and six-weeks post-inoculation with *P. murina*. Graphs indicate mean $\pm$ SD values of triplicate samples. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, by two-sample Welch's t-test corrected for multiple comparisons by the Holm-Sidak method (WT vs. Rag2^{-/-}) or performed without correction (4 vs. 6 weeks post-infection).




Figure 4 Characterization of *Nad4* and *Gsc1* assay performance in spiked samples. (A) Ranked list of the most abundant and differentially detected *P. jirovecii* RNAs identified by sequencing of BAL samples of two *P. jirovecii* positive patients after subtractive hybridization to remove host-derived RNA transcripts. (B) Genomic organization of enriched *P. jirovecii* mitochondrial genes and alignment of the *P. jirovecii* *Nad4* primer and gRNA sequences with corresponding sequence regions of other *Pneumocystis* species (red text denotes sequence mismatches). LoD analyses for the (C) *Nad4* and (D) *Gsc1* CRISPR assays and (E) a matching *Nad4* RT-qPCR assay, and the linear detection range data for the (F) *Nad4* and (G) *Gsc1* CRISPR assays and for RT-qPCR *Nad4*. Species specificity of the *P. jirovecii* (I) *Nad4* and (J) *Gsc1* assays when analyzing samples spiked with corresponding sequences from other respiratory pathogens. NTC = no template control. Graphs indicate mean $\pm$ SD values of triplicate analyses. Standard curve graphs indicate the linear regression line of the data, its 95% CI, and Pearson coefficient.




Figure 5 Characterization of *Nad4* assay performance with infant oropharyngeal swab and adult BAL samples. (A) Heatmap of CRISPR and RT-qPCR assay positive (red) and negative (blue) results for *Nad4* and *Gsc1* in infant oropharyngeal swab and adult BAL samples from *P. jirovecii*-infected and -non-infected patients. *Nad4* levels detected in (B) infant oropharyngeal swab and (C) adult BAL samples from North America, where positive signal was defined as signal that exceeded a threshold of the mean plus three times the SD of triplicate NTC samples (vertical dashed lines). (D and E) Heatmap of CRISPR and RT-qPCR assay positive (red) and negative (blue) results for *Nad4* and *Gsc1* in adult BAL and serum samples from PCP-positive and -negative cases determined by immunofluorescence assay (IFA). *Nad4* levels detected in (F) adult BAL and (G) adult serum samples from patients in South Africa, where positive signal was defined as signal that exceeded a threshold of the mean plus three times the SD of triplicate NTC samples (vertical dashed lines).

742 **TABLES**

743 **Table 1. CRISPR and RT-qPCR assay diagnostic performance using pediatric oropharyngeal swab**
specimens.

Method	Target	Sensitivity	95% CI	Specificity	95% CI
CRISPR	<i>Nad4</i>	96.3%	87.3% to 99.6%	100.0%	93.3% to 100%
CRISPR	<i>Gsc1</i>	72.2%	58.4% to 83.5%	100.0%	93.3% to 100%
RT-qPCR	<i>Nad4</i>	66.7%	52.5% to 78.9%	90.6%	79.3% to 96.9%

759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776

Table 2. CRISPR and qPCR assay diagnostic performance using adult BAL specimens from North America.

Method	Target	Sensitivity	95% CI	Specificity	95% CI
CRISPR	<i>Nad4</i>	91.7%	64.6% to 99.6%	100%	83.9% to 100%
CRISPR	<i>Gsc1</i>	83.3%	55.2% to 97.0%	100%	83.9% to 100%
RT-qPCR	<i>Nad4</i>	66.7%	39.1% to 94.7%	94.7%	75.4% to 99.7%

777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802

Table 3. CRISPR and RT-qPCR assay diagnostic performance using adult BAL specimens from Cape Town, South Africa.

Method	Target	Sensitivity	95% CI	Specificity	95% CI
CRISPR	<i>Nad4</i>	100.0%	78.2% to 100.0%	91.7%	61.5% to 99.8%
CRISPR	<i>Gsc1</i>	73.3%	44.9% to 92.2%	75.0%	42.8% to 94.5%
RT-qPCR	<i>Nad4</i>	60.0%	32.3% to 83.7%	83.3%	51.6% to 98.0%

Table 4. CRISPR and RT-qPCR assay diagnostic performance using adult serum specimens from Cape Town, South Africa.

Method	Target	Sensitivity	95% CI	Specificity	95% CI
CRISPR	<i>Nad4</i>	93.3%	68.1% to 99.8%	91.7%	61.5% to 99.8%
CRISPR	<i>Gsc1</i>	60.0%	32.3% to 83.7%	91.7%	61.5% to 99.8%
RT-qPCR	<i>Nad4</i>	26.7%	7.8% to 55.1%	91.7%	61.5% to 99.8%